Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
Chandler H. Park, MD, MS, FACP
Advertisement
Articles by Chandler H. Park, MD, MS, FACP
Explore the latest advancements in sarcoma immunotherapy, focusing on tumor microenvironment modulation and innovative treatment strategies for improved patient outcomes.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
4
TIP127 TroFuse-012: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab Vs Treatment of Physician’s Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
5